{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:05:49Z","timestamp":1767373549790,"version":"3.37.3"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["01VSF22007","01VSF22007","01VSF22007"],"award-info":[{"award-number":["01VSF22007","01VSF22007","01VSF22007"]}],"id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This executive summary of a German national guideline aims to provide the most relevant evidence-based recommendations on the diagnosis and treatment of nosocomial pneumonia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The guideline made use of a systematic assessment and decision process using evidence to decision framework (GRADE). Recommendations were consented by an interdisciplinary panel. Evidence analysis and interpretation was supported by the German innovation fund providing extensive literature searches and (meta-) analyses by an independent methodologist. For this executive summary, selected key recommendations are presented including the quality of evidence and rationale for the level of recommendation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The original guideline contains 26 recommendations for the diagnosis and treatment of adults with nosocomial pneumonia, thirteen of which are based on systematic review and\/or meta-analysis, while the other 13 represent consensus expert opinion. For this key summary, we present 11 most relevant for everyday clinical practice key recommendations with evidence overview and rationale, of which two are expert consensus and 9 evidence-based (4 strong, 5 weak and 2 open recommendations). For the management of nosocomial pneumonia patients should be divided in those with and without risk factors for multidrug-resistant pathogens and\/or <jats:italic>Pseudomonas aeruginosa<\/jats:italic>. Bacterial multiplex-polymerase chain reaction (PCR) should not be used routinely. Bronchoscopic diagnosis is not considered superior to\u00b4non-bronchoscopic sampling in terms of main outcomes. Only patients with septic shock and the presence of an additional risk factor for multidrug-resistant pathogens (MDRP) should receive empiric combination therapy. In clinically stabilized patients, antibiotic therapy should be de-escalated and focused. In critically ill patients, prolonged application of suitable beta-lactam antibiotics should be preferred. Therapy duration is suggested for 7\u20138\u00a0days. Procalcitonin (PCT) based algorithm might be used to shorten the duration of antibiotic treatment. Patients on the intensive care unit (ICU) are at risk for invasive pulmonary aspergillosis (IPA). Diagnostics for <jats:italic>Aspergillus<\/jats:italic> should be performed with an antigen test from bronchial lavage fluid.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The current guideline focuses on German epidemiology and standards of care. It should be a guide for the current treatment and management of nosocomial pneumonia in Germany.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-024-02358-y","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T14:02:42Z","timestamp":1723125762000},"page":"2531-2545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Key summary of German national guideline for adult patients with nosocomial pneumonia- Update 2024 Funding number at the Federal Joint Committee (G-BA): 01VSF22007"],"prefix":"10.1007","volume":"52","author":[{"given":"Jessica","family":"Rademacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Ewig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Grabein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irit","family":"Nachtigall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Abele-Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Deja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Ga\u00dfner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f6ren","family":"Gatermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Geffers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herwig","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Hagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus Peter","family":"Heu\u00dfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kolditz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Kramme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilmar","family":"K\u00fchl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Panning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter-Michael","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gernot","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Schaaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut J. F.","family":"Salzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dierk","family":"Schreiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Schweisfurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Unverzagt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus A.","family":"Weigand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Welte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"2358_CR1","unstructured":"European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2016\u20132017;2023. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/point-prevalence-survey-healthcare-associated-infections-and-antimicrobial-use-5. Accessed 4 Aug 2024"},{"key":"2358_CR2","unstructured":"European Centre for Disease Prevention and Control, An agency of the European Union. Point prevalence survey database (HAI-Net);2012.https:\/\/www.ecdc.europa.eu\/en\/publications-data\/point-prevalence-survey-healthcare-associated-infections-and-antimicrobial-use-0 . Accessed 4 Aug 2024"},{"key":"2358_CR3","first-page":"851","volume":"114","author":"M Behnke","year":"2017","unstructured":"Behnke M, Aghdassi SJ, Hansen S, Diaz LAP, Gastmeier P, Piening B. The prevalence of nosocomial infection and antibiotic use in German hospitals. Dtsch Arzteblatt Int. 2017;114:851\u20137.","journal-title":"Dtsch Arzteblatt Int."},{"key":"2358_CR4","unstructured":"ECDC. Die Gesundheit in Europa erhalten \u2013 ECDC in Aktion;2013. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/media\/de\/publications\/Publications\/0902_COR_Keeping_Europe_Healthy.pdf. Accessed 4 Aug 2024"},{"key":"2358_CR5","unstructured":"NRZ. Abschlussbericht der Punkt-Pr\u00e4valenzerhebung 2016 zum Vorkommen von nosokomialen Infektionen und zur Anwendung von Antibiotika an Akutkrankenh\u00e4usern in Deutschland;2017. https:\/\/www.nrz-hygiene.de\/files\/Projekte\/PPS%202016\/PPS_2016_Abschlussbericht_20.07.2017.pdf. Accessed 4 Aug 2024"},{"key":"2358_CR6","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1371\/journal.pmed.1002150","volume":"13","author":"A Cassini","year":"2016","unstructured":"Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP, Ducomble T. Burden of six healthcare-associated infections on european population health: estimating incidence-based disability-adjusted life years through a population prevalence-based modelling study. PLoS Med. 2016;13:2150.","journal-title":"PLoS Med"},{"key":"2358_CR7","first-page":"15","volume":"72","author":"K Dalhoff","year":"2018","unstructured":"Dalhoff K, Abele-Horn M, Andreas S, Deja M, Ewig S, Gastmeier P. [Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia - update 2017 - S3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy, the German Radiological Society and the Society for Virology]. Pneumol Stuttg Ger. 2018;72:15\u201363.","journal-title":"Pneumol Stuttg Ger."},{"key":"2358_CR8","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.","journal-title":"BMJ"},{"key":"2358_CR9","unstructured":"AGREE Next Steps Consortium. The AGREE II Instrument [Electronic version]. https:\/\/www.agreetrust.org\/wp-content\/uploads\/2014\/03\/AGREE_II_German-Version.pdf. Accessed 4 Aug 2024"},{"key":"2358_CR10","unstructured":"Oxford Centre for Evidence-Based Medicine. \u201eThe Oxford 2011 Levels of Evidence\u201c. [Internet]. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence. Accessed 4 Aug 2024"},{"key":"2358_CR11","unstructured":"Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. https:\/\/training.cochrane.org\/handbook. Accessed 4 Aug 2024"},{"key":"2358_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401\u20136.","journal-title":"J Clin Epidemiol"},{"key":"2358_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1164\/ajrccm.157.2.9705064","volume":"157","author":"JL Trouillet","year":"1998","unstructured":"Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998;157:531\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"2358_CR14","doi-asserted-by":"publisher","first-page":"R142","DOI":"10.1186\/cc7119","volume":"12","author":"PO Depuydt","year":"2008","unstructured":"Depuydt PO, Vandijck DM, Bekaert MA, Decruyenaere JM, Blot SI, Vogelaers DP. Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia. Crit Care Lond Engl. 2008;12:R142.","journal-title":"Crit Care Lond Engl"},{"key":"2358_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1183\/09031936.02.00267602","volume":"20","author":"O Leroy","year":"2002","unstructured":"Leroy O, Giradie P, Yazdanpanah Y, Georges H, Alfandari S, Sanders V. Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens. Eur Respir J. 2002;20:432\u20139.","journal-title":"Eur Respir J"},{"key":"2358_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.rmed.2016.11.023","volume":"122","author":"AF Shorr","year":"2017","unstructured":"Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Viruses are prevalent in non-ventilated hospital-acquired pneumonia. Respir Med. 2017;122:76\u201380.","journal-title":"Respir Med"},{"key":"2358_CR17","doi-asserted-by":"publisher","first-page":"00028","DOI":"10.1183\/23120541.00028-2018","volume":"4","author":"A Torres","year":"2018","unstructured":"Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H. Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. ERJ Open Res. 2018;4:00028\u20132018.","journal-title":"ERJ Open Res"},{"key":"2358_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.21037\/atm.2018.09.34","volume":"6","author":"B Pilmis","year":"2018","unstructured":"Pilmis B, Zahar JR. Ventilator-associated pneumonia related to ESBL-producing gram negative bacilli. Ann Transl Med. 2018;6:424.","journal-title":"Ann Transl Med"},{"key":"2358_CR19","first-page":"455","volume":"35","author":"R Ferrer","year":"2022","unstructured":"Ferrer R, Soriano A, Cant\u00f3n R, Del Pozo JL, Garc\u00eda-Vidal C, Garnacho-Montero J. A systematic literature review and expert consensus on risk factors associated to infection progression in adult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteria. Rev Espanola Quimioter Publicacion Of Soc Espanola Quimioter. 2022;35:455\u201367.","journal-title":"Rev Espanola Quimioter Publicacion Of Soc Espanola Quimioter"},{"key":"2358_CR20","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1097\/CCM.0000000000000510","volume":"42","author":"MH Kollef","year":"2014","unstructured":"Kollef MH, Chastre J, Fagon JY, Fran\u00e7ois B, Niederman MS, Rello J. Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care Med. 2014;42:2178\u201387.","journal-title":"Crit Care Med"},{"key":"2358_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jcrc.2008.02.001","volume":"23","author":"CM Parker","year":"2008","unstructured":"Parker CM, Kutsogiannis J, Muscedere J, Cook D, Dodek P, Day AG. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care. 2008;23:18\u201326.","journal-title":"J Crit Care"},{"key":"2358_CR22","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s10096-015-2495-6","volume":"34","author":"D Koulenti","year":"2015","unstructured":"Koulenti D, Blot S, Dulhunty JM, Papazian L, Martin-Loeches I, Dimopoulos G. COPD patients with ventilator-associated pneumonia: implications for management. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2015;34:2403\u201311.","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"2358_CR23","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s10096-019-03644-6","volume":"38","author":"F Labaste","year":"2019","unstructured":"Labaste F, Grossac J, Bounes FV, Conil JM, Ruiz S, Seguin T. Risk factors for acquisition of carbapenem-resistance during treatment with carbapenem in the intensive care unit: a prospective study. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2019;38:2077\u201385.","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"2358_CR24","first-page":"8","volume":"24","author":"B Tilahun","year":"2015","unstructured":"Tilahun B, Faust AC, McCorstin P, Ortegon A. Nasal colonization and lower respiratory tract infections with methicillin-resistant Staphylococcus aureus. Am J Crit Care Off Publ Am Assoc Crit-Care Nurses. 2015;24:8\u201312.","journal-title":"Am J Crit Care Off Publ Am Assoc Crit-Care Nurses"},{"key":"2358_CR25","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1128\/AAC.01805-13","volume":"58","author":"B Dangerfield","year":"2014","unstructured":"Dangerfield B, Chung A, Webb B, Seville MT. Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia. Antimicrob Agents Chemother. 2014;58:859\u201364.","journal-title":"Antimicrob Agents Chemother"},{"key":"2358_CR26","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1097\/CCM.0b013e3181eeda3f","volume":"38","author":"KV Sarikonda","year":"2010","unstructured":"Sarikonda KV, Micek ST, Doherty JA, Reichley RM, Warren D, Kollef MH. Methicillin-resistant Staphylococcus aureus nasal colonization is a poor predictor of intensive care unit-acquired methicillin-resistant Staphylococcus aureus infections requiring antibiotic treatment. Crit Care Med. 2010;38:1991\u20135.","journal-title":"Crit Care Med"},{"key":"2358_CR27","first-page":"00086","volume":"S2213\u20132600","author":"AM Darie","year":"2022","unstructured":"Darie AM, Khanna N, Jahn K, Osthoff M, Bassetti S, Osthoff M. Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (flagship II): a multicentre, randomised controlled trial. Lancet Respir Med. 2022;S2213\u20132600:00086\u20138.","journal-title":"Lancet Respir Med"},{"key":"2358_CR28","first-page":"734","volume":"29","author":"M Fartoukh","year":"2023","unstructured":"Fartoukh M, Nseir S, M\u00e9garbane B, Cohen Y, Lafarge A, Contou D. Respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in severe SARS-CoV-2 pneumonia: a multicentre randomized controlled trial. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2023;29:734\u201343.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"2358_CR29","doi-asserted-by":"publisher","first-page":"00595","DOI":"10.1183\/23120541.00595-2021","volume":"8","author":"A Salina","year":"2022","unstructured":"Salina A, Schumann DM, Franchetti L, Jahn K, Purkabiri K, M\u00fcller R. Multiplex bacterial PCR in the bronchoalveolar lavage fluid of non-intubated patients with suspected pulmonary infection: a quasi-experimental study. ERJ Open Res. 2022;8:00595\u20132021.","journal-title":"ERJ Open Res"},{"key":"2358_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jinf.2020.03.065","volume":"81","author":"M Bassetti","year":"2020","unstructured":"Bassetti M, Giacobbe DR, Grecchi C, Rebuffi C, Zuccaro V, Scudeller L. Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: a systematic review with qualitative evidence synthesis. J Infect. 2020;81:131\u201346.","journal-title":"J Infect"},{"key":"2358_CR31","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis Off Publ Infect Dis Soc Am. 2007;44:1289\u201397.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2358_CR32","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1080\/03007995.2018.1502659","volume":"34","author":"R Herbrecht","year":"2018","unstructured":"Herbrecht R, Kuessner D, Pooley N, Posthumus J, Escrig C. Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis. Curr Med Res Opin. 2018;34:2187\u201395.","journal-title":"Curr Med Res Opin"},{"key":"2358_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","volume":"397","author":"JA Maertens","year":"2021","unstructured":"Maertens JA, Rahav G, Lee DG, Ponce-de-Le\u00f3n A, Ram\u00edrez S\u00e1nchez IC, Klimko N. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet Lond Engl. 2021;397:499\u2013509.","journal-title":"Lancet Lond Engl"},{"key":"2358_CR34","first-page":"80","volume":"28","author":"AA Panackal","year":"2014","unstructured":"Panackal AA, Parisini E, Proschan M. Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2014;28:80\u201394.","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"2358_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.diagmicrobio.2018.08.005","volume":"93","author":"L Zhang","year":"2019","unstructured":"Zhang L, Guo Z, Xie S, Zhou J, Chen G, Feng J. The performance of galactomannan in combination with 1,3-\u03b2-D-glucan or aspergillus-lateral flow device for the diagnosis of invasive aspergillosis: evidences from 13 studies. Diagn Microbiol Infect Dis. 2019;93:44\u201353.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2358_CR36","first-page":"CD006482","volume":"10","author":"DC Berton","year":"2014","unstructured":"Berton DC, Kalil AC, Teixeira PJZ. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. Cochrane Database Syst Rev. 2014;10:CD006482.","journal-title":"Cochrane Database Syst Rev"},{"key":"2358_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-132-8-200004180-00004","volume":"132","author":"JY Fagon","year":"2000","unstructured":"Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, St\u00e9phan F. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med. 2000;132:621\u201330.","journal-title":"Ann Intern Med"},{"key":"2358_CR38","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMoa052904","volume":"355","author":"Canadian Critical Care Trials Group","year":"2006","unstructured":"Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006;355:2619\u201330.","journal-title":"N Engl J Med"},{"key":"2358_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1164\/ajrccm.162.1.9907090","volume":"162","author":"M Ruiz","year":"2000","unstructured":"Ruiz M, Torres A, Ewig S, Marcos MA, Alc\u00f3n A, Lled\u00f3 R. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med. 2000;162:119\u201325.","journal-title":"Am J Respir Crit Care Med"},{"key":"2358_CR40","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1164\/ajrccm.157.2.97-02039","volume":"157","author":"JM Sanchez-Nieto","year":"1998","unstructured":"Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, El-Ebiary M, Carrillo A, Ruiz J. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. Am J Respir Crit Care Med. 1998;157:371\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"2358_CR41","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1097\/00003246-200008000-00009","volume":"28","author":"J Sol\u00e9 Viol\u00e1n","year":"2000","unstructured":"Sol\u00e9 Viol\u00e1n J, Fern\u00e1ndez JA, Ben\u00edtez AB, Carde\u00f1osa Cendrero JA, de Castro FR. Impact of quantitative invasive diagnostic techniques in the management and outcome of mechanically ventilated patients with suspected pneumonia. Crit Care Med. 2000;28:2737\u201341.","journal-title":"Crit Care Med"},{"key":"2358_CR42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00134-022-06898-5","volume":"49","author":"I Martin-Loeches","year":"2023","unstructured":"Martin-Loeches I, Chastre J, Wunderink RG. Bronchoscopy for diagnosis of ventilator-associated pneumonia. Intensive Care Med. 2023;49:79\u201382.","journal-title":"Intensive Care Med"},{"key":"2358_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1378\/chest.110.1.172","volume":"110","author":"JF Timsit","year":"1996","unstructured":"Timsit JF, Misset B, Azoulay E, Renaud B, Garrouste-Orgeas M, Carlet J. Usefulness of airway visualization in the diagnosis of nosocomial pneumonia in ventilated patients. Chest. 1996;110:172\u20139.","journal-title":"Chest"},{"key":"2358_CR44","first-page":"984","volume":"12","author":"BG Kim","year":"2023","unstructured":"Kim BG, Kang D, Min KH, Cho J, Jeon K. Comparison of Cefepime with Piperacillin\/Tazobactam treatment in patients with hospital-acquired pneumonia. Antibiot Basel Switz. 2023;12:984.","journal-title":"Antibiot Basel Switz"},{"key":"2358_CR45","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s15010-007-6193-x","volume":"35","author":"G H\u00f6ffken","year":"2007","unstructured":"H\u00f6ffken G, Barth J, Rubinstein E, Beckmann H, HAP study group. A randomized study of sequential intravenous\/oral moxifloxacin in comparison to sequential intravenous ceftriaxone\/oral cefuroxime axetil in patients with hospital-acquired pneumonia. Infection. 2007;35:414\u201320.","journal-title":"Infection"},{"key":"2358_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20108","volume":"9","author":"HQ Cang","year":"2023","unstructured":"Cang HQ, Quan XH, Chu XH, Liang Y, Yang X, Li J. Carbapenems versus \u03b2-lactam and \u03b2-lactamase inhibitors for treatment of nosocomial pneumonia: a systematic review and meta-analysis. Heliyon. 2023;9: e20108.","journal-title":"Heliyon"},{"key":"2358_CR47","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s15010-019-01273-x","volume":"47","author":"S Hagel","year":"2019","unstructured":"Hagel S, Schmitt S, Kesselmeier M, Baier M, Welte T, Ewig S. M. pneumoniae and C. pneumoniae are no relevant pathogens in critically ill patients with hospital-acquired respiratory tract infections. Infection. 2019;47:471\u20134.","journal-title":"Infection"},{"key":"2358_CR48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13054-023-04792-0","volume":"28","author":"F Barbier","year":"2024","unstructured":"Barbier F, Dupuis C, Buetti N, Schwebel C, Azoulay \u00c9, Argaud L. Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study. Crit Care Lond Engl. 2024;28:10.","journal-title":"Crit Care Lond Engl"},{"key":"2358_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/01.CCM.0000297956.27474.9D","volume":"36","author":"MAW Aarts","year":"2008","unstructured":"Aarts MAW, Hancock JN, Heyland D, McLeod RS, Marshall JC. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2008;36:108\u201317.","journal-title":"Crit Care Med"},{"key":"2358_CR50","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1097\/00003246-199710000-00015","volume":"25","author":"B Sieger","year":"1997","unstructured":"Sieger B, Berman SJ, Geckler RW, Farkas SA. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem lower respiratory infection group. Crit Care Med. 1997;25:1663\u201370.","journal-title":"Crit Care Med"},{"key":"2358_CR51","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","volume":"18","author":"M Paul","year":"2018","unstructured":"Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18:391\u2013400.","journal-title":"Lancet Infect Dis"},{"key":"2358_CR52","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1080\/1120009X.2018.1425279","volume":"30","author":"XR Bai","year":"2018","unstructured":"Bai XR, Liu JM, Jiang DC, Yan SY. Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies. J Chemother Florence Italy. 2018;30:172\u20138.","journal-title":"J Chemother Florence Italy"},{"key":"2358_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106512","volume":"59","author":"L Onorato","year":"2022","unstructured":"Onorato L, Macera M, Cal\u00f2 F, Cirillo P, Di Caprio G, Coppola N. Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: a meta-analysis. Int J Antimicrob Agents. 2022;59: 106512.","journal-title":"Int J Antimicrob Agents"},{"key":"2358_CR54","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1097\/CCM.0b013e3181e96b91","volume":"38","author":"A Kumar","year":"2010","unstructured":"Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic\/meta-regression study. Crit Care Med. 2010;38:1651\u201364.","journal-title":"Crit Care Med"},{"key":"2358_CR55","doi-asserted-by":"publisher","first-page":"15290","DOI":"10.1038\/s41598-019-51711-x","volume":"9","author":"A Schmid","year":"2019","unstructured":"Schmid A, Wolfensberger A, Nemeth J, Schreiber PW, Sax H, Kuster SP. Monotherapy versus combination therapy for multidrug-resistant gram-negative infections: systematic review and meta-analysis. Sci Rep. 2019;9:15290.","journal-title":"Sci Rep"},{"key":"2358_CR56","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ijantimicag.2017.12.020","volume":"51","author":"KZ Vardakas","year":"2018","unstructured":"Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME. Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2018;51:535\u201347.","journal-title":"Int J Antimicrob Agents"},{"key":"2358_CR57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jac\/dkw377","volume":"72","author":"O Zusman","year":"2017","unstructured":"Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72:29\u201339.","journal-title":"J Antimicrob Chemother"},{"key":"2358_CR58","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jinf.2016.11.013","volume":"74","author":"F Sj\u00f6vall","year":"2017","unstructured":"Sj\u00f6vall F, Perner A, Hylander MM. Empirical mono- versus combination antibiotic therapy in adult intensive care patients with severe sepsis\u2014a systematic review with meta-analysis and trial sequential analysis. J Infect. 2017;74:331\u201344.","journal-title":"J Infect"},{"key":"2358_CR59","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00134-020-05929-3","volume":"46","author":"N Arulkumaran","year":"2020","unstructured":"Arulkumaran N, Routledge M, Schlebusch S, Lipman J, Conway MA. Antimicrobial-associated harm in critical care: a narrative review. Intensive Care Med. 2020;46:225\u201335.","journal-title":"Intensive Care Med"},{"key":"2358_CR60","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1097\/01.CCM.0000275389.31974.22","volume":"35","author":"J Garnacho-Montero","year":"2007","unstructured":"Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007;35:1888\u201395.","journal-title":"Crit Care Med"},{"key":"2358_CR61","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.41.5.1127","volume":"41","author":"L Leibovici","year":"1997","unstructured":"Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother. 1997;41:1127\u201333.","journal-title":"Antimicrob Agents Chemother"},{"key":"2358_CR62","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/01.CCM.0B013E31816203D6","volume":"36","author":"DK Heyland","year":"2008","unstructured":"Heyland DK, Dodek P, Muscedere J, Day A, Cook D, Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008;36:737\u201344.","journal-title":"Crit Care Med"},{"key":"2358_CR63","first-page":"41","volume":"98","author":"L Aboulatta","year":"2020","unstructured":"Aboulatta L, Sugita H, Wakabayashi H, Noma H, Sasaki T. Comparison of extended versus intermittent infusion of antipseudomonal beta-lactams for the treatment of critically ill patients with respiratory infections: a systematic review and meta-analysis. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2020;98:41\u201350.","journal-title":"Int J Infect Dis IJID Off Publ Int Soc Infect Dis"},{"key":"2358_CR64","doi-asserted-by":"publisher","first-page":"e14632","DOI":"10.1097\/MD.0000000000014632","volume":"98","author":"CH Chen","year":"2019","unstructured":"Chen CH, Chen YM, Chang YJ, Wang SH, Chang CY, Yen HC. Continuous versus intermittent infusions of antibiotics for the treatment of infectious diseases: Meta-analysis and systematic review. Medicine (Baltimore). 2019;98:e14632.","journal-title":"Medicine (Baltimore)"},{"key":"2358_CR65","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12879-020-05149-6","volume":"20","author":"S Fawaz","year":"2020","unstructured":"Fawaz S, Barton S, Nabhani-Gebara S. Comparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients: a systematic review and meta-analysis. BMC Infect Dis. 2020;20:430.","journal-title":"BMC Infect Dis"},{"key":"2358_CR66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s13318-017-0446-6","volume":"43","author":"YR Lee","year":"2018","unstructured":"Lee YR, Miller PD, Alzghari SK, Blanco DD, Hager JD, Kuntz KS. Correction to: continuous infusion versus intermittent bolus of beta-lactams in critically Ill patients with respiratory infections: a systematic review and meta-analysis. Eur J Drug Metab Pharmacokinet. 2018;43:171.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2358_CR67","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","volume":"194","author":"JA Roberts","year":"2016","unstructured":"Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J. Continuous versus intermittent \u03b2-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194:681\u201391.","journal-title":"Am J Respir Crit Care Med"},{"key":"2358_CR68","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12890-016-0202-8","volume":"16","author":"CJ Russell","year":"2016","unstructured":"Russell CJ, Shiroishi MS, Siantz E, Wu BW, Patino CM. The use of inhaled antibiotic therapy in the treatment of ventilator-associated pneumonia and tracheobronchitis: a systematic review. BMC Pulm Med. 2016;16:40.","journal-title":"BMC Pulm Med"},{"key":"2358_CR69","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jcrc.2021.06.004","volume":"65","author":"R Tang","year":"2021","unstructured":"Tang R, Luo R, Wu B, Wang F, Song H, Chen X. Effectiveness and safety of adjunctive inhaled antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. J Crit Care. 2021;65:133\u20139.","journal-title":"J Crit Care"},{"key":"2358_CR70","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/CCM.0000000000000771","volume":"43","author":"A Valachis","year":"2015","unstructured":"Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med. 2015;43:527\u201333.","journal-title":"Crit Care Med"},{"key":"2358_CR71","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s13054-018-2106-x","volume":"22","author":"F Xu","year":"2018","unstructured":"Xu F, He LL, Che LQ, Li W, Ying SM, Chen ZH. Aerosolized antibiotics for ventilator-associated pneumonia: a pairwise and Bayesian network meta-analysis. Crit Care Lond Engl. 2018;22:301.","journal-title":"Crit Care Lond Engl"},{"key":"2358_CR72","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/jamp.2021.0023","volume":"35","author":"LB Palmer","year":"2022","unstructured":"Palmer LB, Smaldone GC. The unfulfilled promise of inhaled therapy in ventilator-associated infections: where do we go from here? J Aerosol Med Pulm Drug Deliv. 2022;35:11\u201324.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2358_CR73","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13054-015-0868-y","volume":"19","author":"FG Zampieri","year":"2015","unstructured":"Zampieri FG, Nassar AP, Gusmao-Flores D, Taniguchi LU, Torres A, Ranzani OT. Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care Lond Engl. 2015;19:150.","journal-title":"Crit Care Lond Engl"},{"key":"2358_CR74","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;63:e61-111.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2358_CR75","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/ALN.0b013e31827515de","volume":"117","author":"Q Lu","year":"2012","unstructured":"Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology. 2012;117:1335\u201347.","journal-title":"Anesthesiology"},{"key":"2358_CR76","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1007\/s00134-005-2697-y","volume":"31","author":"E Giantsou","year":"2005","unstructured":"Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, Kartali-Ktenidou S. Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med. 2005;31:1488\u201394.","journal-title":"Intensive Care Med"},{"key":"2358_CR77","doi-asserted-by":"publisher","first-page":"R78","DOI":"10.1186\/cc4919","volume":"10","author":"F Alvarez-Lerma","year":"2006","unstructured":"Alvarez-Lerma F, Alvarez B, Luque P, Ruiz F, Dominguez-Roldan JM, Quintana E. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care Lond Engl. 2006;10:R78.","journal-title":"Crit Care Lond Engl"},{"key":"2358_CR78","first-page":"1343","volume":"66","author":"SR Eachempati","year":"2009","unstructured":"Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically Ill surgical patients? J Trauma. 2009;66:1343\u20138.","journal-title":"J Trauma"},{"key":"2358_CR79","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1080\/23744235.2016.1277035","volume":"49","author":"L Deconinck","year":"2017","unstructured":"Deconinck L, Meybeck A, Patoz P, Van Grunderbeeck N, Boussekey N, Chiche A. Impact of combination therapy and early de-escalation on outcome of ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Infect Dis Lond Engl. 2017;49:396\u2013404.","journal-title":"Infect Dis Lond Engl"},{"key":"2358_CR80","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s11096-017-0499-2","volume":"39","author":"RA Khan","year":"2017","unstructured":"Khan RA, Aziz Z. A retrospective study of antibiotic de-escalation in patients with ventilator-associated pneumonia in Malaysia. Int J Clin Pharm. 2017;39:906\u201312.","journal-title":"Int J Clin Pharm"},{"key":"2358_CR81","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.4103\/0366-6999.231529","volume":"131","author":"H Li","year":"2018","unstructured":"Li H, Yang CH, Huang LO, Cui YH, Xu D, Wu CR. Antibiotics de-escalation in the treatment of ventilator-associated pneumonia in trauma patients: a retrospective study on propensity score matching method. Chin Med J (Engl). 2018;131:1151\u20137.","journal-title":"Chin Med J (Engl)"},{"key":"2358_CR82","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jcrc.2007.12.006","volume":"23","author":"AR Joffe","year":"2008","unstructured":"Joffe AR, Muscedere J, Marshall JC, Su Y, Heyland DK, Canadian Critical Care Trials Group. The safety of targeted antibiotic therapy for ventilator-associated pneumonia: a multicenter observational study. J Crit Care. 2008;23:82\u201390.","journal-title":"J Crit Care"},{"key":"2358_CR83","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/cc10072","volume":"15","author":"MK Joung","year":"2011","unstructured":"Joung MK, Lee JA, Moon SY, Cheong HS, Joo EJ, Ha YE. Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. Crit Care Lond Engl. 2011;15:R79.","journal-title":"Crit Care Lond Engl"},{"key":"2358_CR84","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/cid\/cit223","volume":"57","author":"C Pe\u00f1a","year":"2013","unstructured":"Pe\u00f1a C, Suarez C, Ocampo-Sosa A, Murillas J, Almirante B, Pomar V. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57:208\u201316.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"2358_CR85","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00134-022-06690-5","volume":"48","author":"A Bougl\u00e9","year":"2022","unstructured":"Bougl\u00e9 A, Tuffet S, Federici L, Leone M, Monsel A, Dessalle T. Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial. Intensive Care Med. 2022;48:841\u20139.","journal-title":"Intensive Care Med"},{"key":"2358_CR86","doi-asserted-by":"publisher","first-page":"e41290","DOI":"10.1371\/journal.pone.0041290","volume":"7","author":"G Capellier","year":"2012","unstructured":"Capellier G, Mockly H, Charpentier C, Annane D, Blasco G, Desmettre T. Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. Spellberg B, Herausgeber. PLoS\u00a0One. 2012;7:e41290.","journal-title":"PLoS\u00a0One"},{"key":"2358_CR87","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","volume":"290","author":"J Chastre","year":"2003","unstructured":"Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290:2588.","journal-title":"JAMA"},{"key":"2358_CR88","doi-asserted-by":"publisher","first-page":"R218","DOI":"10.1186\/cc11862","volume":"16","author":"MH Kollef","year":"2012","unstructured":"Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care. 2012;16:R218.","journal-title":"Crit Care"},{"key":"2358_CR89","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.annfar.2008.10.021","volume":"28","author":"M Fekih Hassen","year":"2009","unstructured":"Fekih Hassen M, Ayed S, Ben Sik Ali H, Gharbi R, Marghli S, Elatrous S. Dur\u00e9e de l\u2019antibioth\u00e9rapie lors du traitement des pneumopathies acquises sous ventilation m\u00e9canique\u202f: comparaison entre sept jours et dix jours \u00c9tude pilote. Ann Fr Anesth R\u00e9animation. 2009;28:16\u201323.","journal-title":"Ann Fr Anesth R\u00e9animation"},{"key":"2358_CR90","doi-asserted-by":"publisher","first-page":"101880","DOI":"10.1016\/j.eclinm.2023.101880","volume":"58","author":"MA Daghmouri","year":"2023","unstructured":"Daghmouri MA, Dugnon E, Chaouch MA, Baekgaard J, Bougle A, Leone M. Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. EClinicalMedicine. 2023;58:101880.","journal-title":"EClinicalMedicine"},{"key":"2358_CR91","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/cid\/ciac784","volume":"76","author":"OR Albin","year":"2023","unstructured":"Albin OR, Kaye KS, McCreary EK, Pogue JM. Less is more? Antibiotic treatment duration in Pseudomonas aeruginosa ventilator-associated pneumonia. Clin Infect Dis. 2023;76:745\u20139.","journal-title":"Clin Infect Dis"},{"key":"2358_CR92","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.cmi.2019.07.019","volume":"26","author":"M Abbas","year":"2020","unstructured":"Abbas M, Rossel A, De Kraker MEA, Von Dach E, Marti C, Emonet S. Association between treatment duration and mortality or relapse in adult patients with Staphylococcus aureus bacteraemia: a retrospective cohort study. Clin Microbiol Infect. 2020;26:626\u201331.","journal-title":"Clin Microbiol Infect"},{"key":"2358_CR93","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ. Clinical Practice Guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-55.","journal-title":"Clin Infect Dis"},{"key":"2358_CR94","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/5584_2020_591","volume":"1323","author":"F Alessandri","year":"2021","unstructured":"Alessandri F, Pugliese F, Angeletti S, Ciccozzi M, Russo A, Mastroianni CM. Procalcitonin in the assessment of ventilator associated pneumonia: a systematic review. Adv Exp Med Biol. 2021;1323:103\u201314.","journal-title":"Adv Exp Med Biol"},{"key":"2358_CR95","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jcrc.2019.05.022","volume":"53","author":"F Beye","year":"2019","unstructured":"Beye F, Vigneron C, Dargent A, Prin S, Andreu P, Large A. Adhering to the procalcitonin algorithm allows antibiotic therapy to be shortened in patients with ventilator-associated pneumonia. J Crit Care. 2019;53:125\u201331.","journal-title":"J Crit Care"},{"key":"2358_CR96","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","volume":"375","author":"L Bouadma","year":"2010","unstructured":"Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C. Use of procalcitonin to reduce patients\u2019 exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. The Lancet. 2010;375:463\u201374.","journal-title":"The Lancet"},{"key":"2358_CR97","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","volume":"16","author":"E de Jong","year":"2016","unstructured":"de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16:819.","journal-title":"Lancet Infect Dis"},{"key":"2358_CR98","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5114\/ait.2021.104300","volume":"53","author":"ZM Mazlan","year":"2021","unstructured":"Mazlan ZM, Ismail AHM, Ali S, Salmuna ZN, Wan Muhd Shukeri WF, Omar M. Efficacy and safety of the point-of-care procalcitonin test for determining the antibiotic treatment duration in patients with ventilator-associated pneumonia in the intensive care unit: a randomised controlled trial. Anaesthesiol Intensive Ther. 2021;53:207\u201314.","journal-title":"Anaesthesiol Intensive Ther"},{"key":"2358_CR99","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1183\/09031936.00053209","volume":"34","author":"D Stolz","year":"2009","unstructured":"Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J. 2009;34:1364\u201375.","journal-title":"Eur Respir J"},{"key":"2358_CR100","doi-asserted-by":"publisher","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"A Torres","year":"2017","unstructured":"Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H. International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT). Eur Respir J. 2017;50:1700582.","journal-title":"Eur Respir J"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02358-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02358-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02358-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T20:02:29Z","timestamp":1733428949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02358-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2358"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02358-y","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"type":"print","value":"0300-8126"},{"type":"electronic","value":"1439-0973"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"11 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JR received research support from Bundesministerium f\u00fcr Bildung und Forschung (BMBF), Bundesministerium f\u00fcr Gesundheit (BMG) Infectopharm; lecture fees from AstraZeneca, GSK, Chiesi, Esanum, Novartis, ThermoFisher, Berlin-Chemie, MSD, Boehringer, Pfizer, Shionogi; Consultant fees from Shionogi, GSK, Advanz, Gilead, MSD BG received lecture fees from Biotest, Gilead, Infectopharm, MIP, MSD, Pfizer and Shionogi; consultant fees from MSD, Pfizer, Gilead und Mundipharma. SG received speaker fees from Becton Dickinson, bioM\u00e9rieux and Bio-Rad.  SH received research support from Bundesministerium f\u00fcr Bildung und Forschung (BMBF); lecture fees from Pfizer, MSD, Infectopharm, Philips, Advanz, Beckman Coulter, Thermofisher, Shionogi, Tillots; Consultant fees from Advanz, Shionogi, Pfizer CPH received personal fees from Schering-Plough; grants and personal fees from Pfizer, Boehringer Ingelheim, Siemens; personal fees from Basilea, Novartis, Roche, Astellas, Gilead, MSD, Lilly, Intermune, Fresenius, Essex, AstraZeneca, Bracco, MEDA Pharma, Chiesi, Covidien, Pierre Fabre, Grifols, Bayer; and grants from MeVis, German Center for Lung Research. SK received research support from Cytosorbents and Daiichi Sankyo; lecture fees from ADVITOS, Biotest, Daiichi Sankyo, Fresenius Medical Care, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer, Shionogi and Zoll; consultant fees from ADVITOS, Fresenius, Gilead, MSD and Pfizer. MK received research support from Pfizer; lecture fees from Astra-Zeneca, Berlin-Chemie, B\u00f6hringer-Ingelheim, Gilead, GSK, Insmed, Pfizer; consultant fees from AstraZeneca, Sanofi, GSK, Insmed MP received lecture fees from Siemens Healthineers, Roche, Janssen-Cilag, Diasorin; consultant fees from Sanofi, GR received support for research from BMBF, GSK, and honoraria from AstraZeneca, Boehringer, Bayer, Berlin-Chemie, Grifols, Insmed, MSD, Novartis, Pfizer, GSK, Roche. H.J.F. Salzer received honoraria for lectures or consulting fees from Insmed, GlaxoSmithKline, AstraZeneca, Advanz Pharma, MSD and Chiesi,  MAW reports personal fees from MSD, Gilead, Pfizer, Shionogi, Mundipharma, Eumedica, Coulter, Biotest, Sedana, SOBI, and B\u00f6hringer; and patent EPA17198330 \u201cDelta- Like Ligand 1 for diagnosing severe infections\u201d. TW received support for research from DFG, BMBF, GSK, and honoraria for lectures\/ad board from AstraZeneca, GSK, Jansen, Moderna, MSD, Pfizer, Sanofi-Aventis. TW provides unpaid advice to Leopoldina, EMA, CDC and is honorary Chairman of the Board of Trustees of CAPNETZ Foundation,  MWP received support for research from DFG, BMBF, EKFS, Manchot Foundation, Sonnenfeld Foundation, Aptarion, Biotest, Pantherna, Vaxxilon, and honoraria from Aptarion, AstraZeneca, Biotest, Chiesi, Gilead, Insmed, Pantherna, Vaxxilon. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}